1 unchanged sentence
Insider Trading Arrangements
−Removed: During the quarter ended November 30, 2025, none of our directors or officers (as defined in Section 16 of the Securities Exchange Act of 1934, as amended) or the Company adopted or terminated a "Rule 10b5-1 trading arrangement" or a "non-Rule 10b5-1 trading arrangement" (each as defined in Item 408(a) and (c), respectively, of Regulation S-K).
+Added: During the quarter ended February 28, 2026, none of our directors or officers (as defined in Section 16 of the Securities Exchange Act of 1934, as amended) or the Company adopted or terminated a "Rule 10b5-1 trading arrangement" or a "non-Rule 10b5-1 trading arrangement" (each as defined in Item 408(a) and (c), respectively, of Regulation S-K).
Table of Content
1 unchanged sentence
Description Form Exhibit Filing Date
+Added: 10.1 Transition and Retirement Agreement, dated as of February 3, 2026, by and between AngioDynamics, Inc.
+Added: 8-K 10.1 February 3, 2026
+Added: 10.2 Form of AngioDynamics Retention Incentive Letter Agreement
+Added: 8-K 10.2 February 3, 2026
31.1 Certification pursuant to Rule 13a-14(a) or 15d-14 under the Securities Exchange Act of 1934
12 unchanged sentences
ANGIODYNAMICS, INC.
−Removed: January 6, 2026 / S / JAMES C.
+Added: April 2, 2026 / S / JAMES C.
Clemmer, President,
1 unchanged sentence
(Principal Executive Officer)
−Removed: January 6, 2026 / S / STEPHEN A.
+Added: April 2, 2026 / S / STEPHEN A.
Trowbridge, Executive Vice President,
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.